ProductLife Group (PLG, Paris, France) has announced the acquisition of ELC Group, a Czech Republic-based regulatory consulting firm with 150 employees.
The strategic merger with ELC comes two months after the acquisition of US-based regulatory drug development consultancy DSI and helps to further accelerate the execution of PLG’s strategic plan, BoOst 2023, which aims to make PLG the worldwide leader in regulatory affairs and compliance. The new group will now include more than 600 staff members located in 40 countries.
“This is a landmark acquisition for PLG that complements our domain expertise and brings enhanced capabilities to our solutions, enabling us to provide sustainable business value to our clients. Adding offshore delivery capability in such a key location as India expands our ability to meet this goal,” commented Xavier Duburcq, PLG CEO.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.